C57.00 - Malignant neoplasm of unspecified fallopian tube
| ICD-10: | C57.00 |
| Short Description: | Malignant neoplasm of unspecified fallopian tube |
| Long Description: | Malignant neoplasm of unspecified fallopian tube |
| Status: | Valid for Submission |
| Version: | ICD-10-CM 2023 |
| Code Classification: |
C57.00 is a billable ICD-10 code used to specify a medical diagnosis of malignant neoplasm of unspecified fallopian tube. The code is valid during the fiscal year 2023 from October 01, 2022 through September 30, 2023 for the submission of HIPAA-covered transactions.
This code is applicable to female patients only. It is clinically and virtually impossible to use this code on a non-female patient.
The following anatomical sites found in the Table of Neoplasms reference the parent code C57.0 of the current diagnosis code given the correct histological behavior: Neoplasm, neoplastic fallopian tube (accessory) or Neoplasm, neoplastic oviduct or Neoplasm, neoplastic salpinx (uterine) or Neoplasm, neoplastic uterus, uteri, uterine tube .
Unspecified diagnosis codes like C57.00 are acceptable when clinical information is unknown or not available about a particular condition. Although a more specific code is preferable, unspecified codes should be used when such codes most accurately reflect what is known about a patient's condition. Specific diagnosis codes should not be used if not supported by the patient's medical record.
Approximate Synonyms
The following clinical terms are approximate synonyms or lay terms that might be used to identify the correct diagnosis code:
- Any T/Any N and M1
- Carcinoma of fallopian tube
- Malignant tumor involving an organ by direct extension from fallopian tube
- Malignant tumor involving an organ by separate metastasis from fallopian tube
- Malignant tumor involving bladder by direct extension from fallopian tube
- Malignant tumor involving bladder by separate metastasis from fallopian tube
- Malignant tumor involving left ovary by direct extension from fallopian tube
- Malignant tumor involving left ovary by separate metastasis from fallopian tube
- Malignant tumor involving rectum by direct extension from fallopian tube
- Malignant tumor involving rectum by separate metastasis from fallopian tube
- Malignant tumor involving right ovary by separate metastasis from fallopian tube
- Malignant tumor involving uterine cervix by direct extension from fallopian tube
- Malignant tumor involving uterine cervix by separate metastasis from fallopian tube
- Malignant tumor involving uterine corpus by direct extension from fallopian tube
- Malignant tumor involving uterine corpus by separate metastasis from fallopian tube
- Malignant tumor involving vagina by direct extension from fallopian tube
- Malignant tumor involving vagina by separate metastasis from fallopian tube
- Malignant tumor involving vulva by direct extension from fallopian tube
- Malignant tumor involving vulva by separate metastasis from fallopian tube
- Malignant tumor of fallopian tube
- pM1
- pN1
- Primary adenocarcinoma of fallopian tube
- Primary malignant neoplasm of fallopian tube
- pT1
- pT1a
- pT1c
- pT1c category
- pT2
- pT2a
- pT2b
- pT2c
- pT2c category
- pT3
- pT3 and/or N1
- pT3a
- pT3b
- pT3c
- pT3c and/or N1
- pT3c category
- Secondary malignant neoplasm of body of uterus
- Secondary malignant neoplasm of cervix uteri
- Secondary malignant neoplasm of left ovary
- Secondary malignant neoplasm of rectum
- Secondary malignant neoplasm of right ovary
- Secondary malignant neoplasm of vagina
- Secondary malignant neoplasm of vulva
- T1
- T1a : Tumor limited to one fallopian tube without penetrating the serosal surface, no ascites
- T1c with extension into or through the tubal serosa; or with malignant cells in ascites or peritoneal washings: FALLOPIAN TUBE: Salpingectomy
- T2 with pelvic extension
- T2a : Fallopian tube tumor with extension and/or metastasis to the uterus and/or ovaries
- T2b : Fallopian tube/ovarian tumor with extension to other pelvic structures
- T2c with malignant cells in ascites or peritoneal washings
- T3 and/or N1 with peritoneal implants outside the pelvis and/or regional lymph node metastasis
- T3a : Fallopian tube/ovarian tumor with microscopic peritoneal metastasis beyond pelvis
- T3b : Fallopian tube/ovarian tumor with macroscopic peritoneal metastasis beyond pelvis < 2 cm in greatest dimension
- T3c : Fallopian tube/ovarian tumor with peritoneal metastasis beyond pelvis > 2 cm in greatest dimension and/or regional lymph node metastasis
- Tubo-ovarian mass
Code Edits
The Medicare Code Editor (MCE) detects and reports errors in the coding of claims data. The following ICD-10 Code Edits are applicable to this code:
- Diagnoses for females only - The Medicare Code Editor detects inconsistencies between a patient’s sex and any diagnosis on the patient’s record, these edits apply to FEMALES only .
Convert to ICD-9 Code
| Source ICD-10 Code | Target ICD-9 Code | |
|---|---|---|
| C57.00 | 183.2 - Mal neo fallopian tube | |
| Approximate Flag - The approximate mapping means there is not an exact match between the ICD-10 and ICD-9 codes and the mapped code is not a precise representation of the original code. | ||
Table of Neoplasms
The parent code C57.0 of the current diagnosis code is referenced in the table of neoplasms by anatomical site. For each site there are six possible code numbers according to whether the neoplasm in question is malignant, benign, in situ, of uncertain behavior, or of unspecified nature. The description of the neoplasm will often indicate which of the six columns is appropriate.
Where such descriptors are not present, the remainder of the Index should be consulted where guidance is given to the appropriate column for each morphological (histological) variety listed. However, the guidance in the Index can be overridden if one of the descriptors mentioned above is present.
| Neoplasm, neoplastic | Malignant Primary |
Malignant Secondary |
CaInSitu | Benign | Uncertain Behavior |
Unspecified Behavior |
|---|---|---|---|---|---|---|
| »Neoplasm, neoplastic »fallopian tube (accessory) | C57.0 | C79.82 | D07.39 | D28.2 | D39.8 | D49.59 |
| »Neoplasm, neoplastic »oviduct | C57.0 | C79.82 | D07.39 | D28.2 | D39.8 | D49.59 |
| »Neoplasm, neoplastic »salpinx (uterine) | C57.0 | C79.82 | D07.39 | D28.2 | D39.8 | D49.59 |
| »Neoplasm, neoplastic »uterus, uteri, uterine »tube | C57.0 | C79.82 | D07.39 | D28.2 | D39.8 | D49.59 |
Patient Education
Uterine Cancer
The uterus, or womb, is the place where a baby grows when a women is pregnant. There are different types of uterine cancer. The most common type starts in the endometrium, the lining of the uterus. This type is also called endometrial cancer.
The symptoms of uterine cancer include:
- Abnormal vaginal bleeding or discharge
- Trouble urinating
- Pelvic pain
- Pain during intercourse
Uterine cancer usually happens after menopause. It is more common in women who have obesity. You also have a higher risk if you took estrogen-only hormone replacement therapy (menopausal hormone therapy) for many years.
Tests to find uterine cancer include a pelvic exam, imaging tests, and a biopsy. The most common treatment is a hysterectomy, which is surgery to remove the uterus. Sometimes the surgery also removes the ovaries and fallopian tubes. Other treatments include hormone therapy, radiation therapy, and chemotherapy. Some women get more than one type of treatment.
NIH: National Cancer Institute
[Learn More in MedlinePlus]
Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ®)
Learn about ovarian epithelial, fallopian tube, and primary peritoneal cancer risk factors, symptoms, tests to diagnose, factors affecting prognosis, staging, and treatment.[Learn More in MedlinePlus]
Code History
- FY 2023 - No Change, effective from 10/1/2022 through 9/30/2023
- FY 2022 - No Change, effective from 10/1/2021 through 9/30/2022
- FY 2021 - No Change, effective from 10/1/2020 through 9/30/2021
- FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020
- FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019
- FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018
- FY 2017 - No Change, effective from 10/1/2016 through 9/30/2017
- FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016 (First year ICD-10-CM implemented into the HIPAA code set)
